ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis.
He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, Karin M. · 2023
Read ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. by He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, Karin M. (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc11332364.txt.
Introduction
He and colleagues show that a stress protein protects against liver cancer by blocking iron-driven cell death in this 2023 study. Liver cancer is a leading cause of cancer death, tied to viral hepatitis, fatty liver disease, and alcohol damage. All three stress the cell's protein-folding compartment and trigger cell death and inflammation. One stress effector, ATF4, had an unknown role in this cancer.
In stress-prone mice fed a high-fat diet, removing ATF4 from liver cells worsened fatty liver cancer, they found. ATF4 switches on a transporter called SLC7A11, also known as xCT. That transporter blocks ferroptosis, the iron-driven death path. Restoring the transporter in ATF4-deficient liver cells restored protection. The authors conclude ATF4 suppresses liver tumour formation through this axis. The work names a concrete stress-to-death pathway in the liver.
Catalog record
| CREATOR | He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, Karin M. |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 69 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis By Feng He, Peng Zhang, Junlai Liu, Ruolei Wang, Randal J Kaufman, Benjamin C Yaden, Michael Karin Published in: Journal of hepatology DOI: 10.1016/j.jhep.2023.03.016 ABSTRACT Abstract Background & Aims: Hepatocellular carcinoma (HCC), a leading cause of cancer-related death, is associated with viral hepatitis, non-alcoholic steatohepatitis (NASH), and alcohol-related steatohepatitis, all of which trigger endoplasmic reticulum (ER) stress, hepatocyte death, inflammation, and compensatory proliferation. Using ER stress-prone MUP-uPA mice, we established that ER stress and hypernutrition cooperate to cause NASH and HCC, but the contribution of individual stress effectors, such as activating transcription factor 4 (ATF4), to HCC and their underlying mechanisms of action remained unknown. Methods: Hepatocyte-specific ATF4-deficient MUP-uPA mice (MUP-uPA/Atf4Δhep) and control MUP-uPA/Atf4F/F mice were fed a high-fat diet to induce NASH-related HCC, and Atf4F/F and Atf4Δhep mice were injected with diethylnitrosamine to model carcinogen-induced HCC. Histological, biochemical, and RNA-sequencing analyses were performed to identify and define the role of ATF4-induced solute carrier family 7a member 11 (SLC7A11) expression in hepatocarcinogenesis. Reconstitution of SLC7A11 in ATF4-deficient primary hepatocytes and mouse livers was used to study its effects on ferroptosis and HCC development. Results: Hepatocyte ATF4 ablation inhibited hepatic steatosis, but increased susceptibility to ferroptosis, resulting in accelerated HCC development. Although ATF4 activates numerous genes, ferroptosis susceptibility and hepatocarcinogenesis were reversed by ectopic expression of a single ATF4 target, Slc7a11, coding for a subunit of the cystine/glutamate antiporter xCT, which is needed for glutathione synthesis. A ferroptosis inhibitor also reduced liver damage and inflammation. ATF4 and SLC7A11 amounts were positively correlated in human HCC and livers of patients with NASH. Conclusions: Despite ATF4 being upregulated in established HCC, it serves an important protective function in normal hepatocytes. By maintaining glutathione production, ATF4 inhibits ferroptosis-dependent inflammatory cell death, which is known to promote compensatory proliferation and hepatocarcinogenesis. Ferroptosis inhibitors or ATF4 activators may also blunt HCC onset. Keywords: HCC, Steatohepatitis, ER stress, ATF4, SLC7A11, NRF2, Ferroptosis INTRODUCTION Liver cancer is the third leading cause of cancer death and the sixth most common cancer type worldwide,1 whose prevalence constantly increases, paralleling the global rise in obesity, type 2 diabetes, metabolic syndrome, and excessive alcohol intake.2,3 Hepatocellular carcinoma (HCC), the main primary liver cancer, is associated with multiple aetiologies, including HBV and HCV infections, non-alcoholic (NAFLD), alcoholic (AFLD), and toxicant-associated (TAFLD) fatty liver diseases, which cause endoplasmic reticulum (ER) stress, liver damage, hepatocyte death, and inflammation. The spectrum of fatty liver disease ranges from simple steatosis without liver damage to steatohepatitis (non-alcoholic steatohepatitis [NASH], alcoholic steatohepatitis [ASH], or toxicant-associated steatohepatitis [TASH] according to their main cause), fibrosis, cirrhosis, and eventually HCC. Despite tight associations with well-defined risk factors, HCC is often diagnosed at an advanced stage, when the main therapeutic options are surgical and radiological ablations and localised chemotherapy. Currently, there are no curative treatments for late-stage HCC, whose median overall survival remains at about 1 year.4 Despite advances in NAFLD/NASH, AFLD/ASH, and TAFLD/TASH diagnosis and aetio-logical understanding, the mechanisms that govern progression from steatohepatitis to HCC remain elusive. Oxidative stress, ER stress, cell death, mitochondrial dysfunction, insulin resistance, inflammation, and gut dysbiosis were shown to be involved in steatohepatitis and its progression to HCC.2,3,5–7 We established the importance of excessive hepatocyte death, necroinflammation, and compensatory proliferation in HCC development.5,7,8 Nonetheless, the type of cell death promoting inflammation and HCC is contentious, with different studies suggesting it could be necrosis, apoptosis, or necroptosis.9–11 Ferroptosis is an iron-dependent cell death type that is often accompanied by lipid peroxidation caused by depletion of reduced glutathione (GSH), decreased glutathione peroxidase 4 (GPX4) activity, or increased lipid peroxidation.12 Ferroptosis is negatively regulated by solute carrier family 7a member 11 (SLC7A11), GPX4, and GSH. In previous studies conducted with hepatocyte-specific IKKβ knockout mice (IkkbΔhep), which are highly susceptible to diethylnitrosamine (DEN)-induced hepatocarcinogenesis, we observed increased lipid peroxidation and hepatocyte death, which were reversed by feeding the mice with N-acetyl cysteine (NAC), a precursor for GSH synthesis.8 A key regulator of ferroptosis is transcription factor nuclear factor erythroid 2-related factor 2 (NRF2), whose activation in HCC and elsewhere is promoted by SQSTM1/p62,5 which is encoded by an IKKβ/NF-κB-inducible gene.13 NRF2 induces SLC7A11 transcription, which is often elevated in human cancers and accompanied by decreased ferroptosis, increased tumour growth, and drug resistance.14,15 Ferroptosis may also be involved in liver injury and inflammation,16 but its role in hepatocarcinogenesis is unknown. Here we explored the role of the ER stress mediator activating transcription factor 4 (ATF4) in DEN- and high-fat diet (HFD)-induced HCC in major urinary protein (MUP)–urokinase-type plasminogen activator (uPA) mice, which express the secreted protein uPA from the MUP promoter. MUP-uPA mice undergo transient hepatic ER stress early in life owing to elevated uPA expression, which is sustained by HFD feeding.7 Using chemical chaperones, we demonstrated that NASH development in these mice depends on ER stress. Protein misfolding after overexpression of a secreted protein triggers the unfolded protein response (UPR), which promotes stress adaptation.17 There are three primary UPR effectors: inositol-requiring enzyme 1 (IRE1), which controls expression of X-box-binding protein 1 (XBP1); activating transcription factor 6 (ATF6); and pancreatic ER-regulating kinase (PERK), which phosphorylates eukaryotic translation initiation factor 2 subunit α (eIF2α) to induce ATF4 translation. ATF4 activates numerous target genes, whose products mitigate stress or induce cell death if the stress cannot be resolved.17 UPR activation is often observed in cancer cells and thought to provide them with a survival advantage.17,18 Hepatocyte-specific IRE1a ablation decreases DEN-induced HCC and blunts acceleration of HCC progression by HFD,19 although it increases acute liver injury and hepatic steatosis.20,21 In contrast, XBP1 loss promotes tumorigenesis in mouse models of intestinal cancer,22 and hepatocyte-specific XBP1 ablation enhanced liver injury and fibrosis but attenuated steatosis in a high-fat/sugar diet-induced NASH model.23 ATF6 activates transformation-associated genes during hepatocarcinogenesis,24 whereas PERK promotes MYC-driven cell transformation and autophagy.25 ATF4 activates genes involved in redox homoeostasis, amino acid (AA) metabolism, protein synthesis, apoptosis, and autophagy,17,26 and was extensively studied for its roles in glucose, lipid, and cholesterol metabolism.27–29 Systemic ATF4 ablation attenuates fructose-induced hyper-triglyceridaemia and hepatic steatosis,30,31 in part through regulation of fibroblast growth factor 21 (FGF21) expression.32 In other studies, ATF4 ablation inhibited hepatic steatosis through different mechanisms, including expression of N-nicotinamide methyltransferase (NNMT)33, tribbles homologue 3 (TRB3),34 or nuclear respiratory factor 1 (NRF1)–mitochondrial transcription factor A (TFAM) signalling.35 ATF4 expression is low in healthy cells but is often elevated in cancer, where it promotes cell survival and tumour growth by inducing genes involved in AA metabolism and oxidant defenses.26,36,37 To test the role of ATF4 in hepatocarcinogenesis, we generated Atf4Δhep mice lacking hepatocyte ATF4. Despite its documented ability to support hepatic steatosis, ATF4 ablation enhanced DEN-induced tumorigenesis and NASH to HCC progression in HFD-fed MUP-uPA mice. Notably, the HCC suppressive activity of ATF4 was mainly caused by expression of a single target, SLC7A11, the small subunit of the cystine/glutamate antiporter (xCT), which is needed for GSH synthesis. Ectopic SLC7A11 expression suppressed HCC development in Atf4Δhep mice and provided protection from ferroptosis, suggesting that ferroptosis contributes to the HCC-promoting necroinflammatory response and that ferroptosis inhibitors may prevent NASH to HCC progression. MATERIALS AND METHODS Mouse models Atf4F/F mice, a generous gift from Dr Christopher Adams (University of Iowa,